A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer

A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer

BackgroundCurrently, approved first-line treatment options of metastatic hormone-sensitive prostate cancer (mHSPC) include (1) androgen deprivation therapy (ADT) alone, ADT plus one of the following: (2) docetaxel, (3) abiraterone, (4) enzalutamide, and (5) apalutamide. The high cost of novel androg...

Full description

Bibliographic Details
Main Authors: Winnie W. Y. Sung, Horace C. W. Choi, Peter H. Y. Luk, Tsz Him So
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
prostate cancer
abiraterone (AA)
enzalutamide (ENZ)
apalutamide
docetaxel
cost effectiveness
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.627083/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.627083/full

Similar Items